首页> 美国卫生研究院文献>Elsevier Sponsored Documents >Systematic review and meta-analysis of experimental studies evaluating the organ protective effects of histone deacetylase inhibitors
【2h】

Systematic review and meta-analysis of experimental studies evaluating the organ protective effects of histone deacetylase inhibitors

机译:评价组蛋白脱乙酰基酶抑制剂的器官保护作用的实验研究的系统综述和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The clinical efficacy of organ protection interventions are limited by the redundancy of cellular activation mechanisms. Interventions that target epigenetic mechanisms overcome this by eliciting genome wide changes in transcription and signaling. We aimed to review preclinical studies evaluating the organ protection effects of histone deacetylase inhibitors (HDACi) with a view to informing the design of early phase clinical trials. A systematic literature search was performed. Methodological quality was assessed against prespecified criteria. The primary outcome was mortality, with secondary outcomes assessing mechanisms. Prespecified analyses evaluated the effects of likely moderators on heterogeneity. The analysis included 101 experimental studies in rodents (n = 92) and swine (n = 9), exposed to diverse injuries, including: ischemia (n = 72), infection (n = 7), and trauma (n = 22). There were a total of 448 comparisons due to the evaluation of multiple independent interventions within single studies. Sodium valproate (VPA) was the most commonly evaluated HDACi (50 studies, 203 comparisons). All of the studies were judged to have significant methodological limitations. HDACi reduced mortality in experimental models of organ injury (risk ratio = 0.52, 95% confidence interval 0.40–0.68, p < 0.001) without heterogeneity. HDACi administration resulted in myocardial, brain and kidney protection across diverse species and injuries that was attributable to increases in prosurvival cell signaling, and reductions in inflammation and programmed cell death. Heterogeneity in the analyses of secondary outcomes was explained by differences in species, type of injury, HDACi class (Class I better), drug (trichostatin better), and time of administration (at least 6 hours prior to injury better). These findings highlight a potential novel application for HDACi in clinical settings characterized by acute organ injury.
机译:器官保护干预措施的临床疗效受到细胞激活机制冗余的限制。针对表观遗传机制的干预措施通过引发转录和信号转导中的全基因组变化来克服这一问题。我们旨在审查评估组蛋白脱乙酰基酶抑制剂(HDACi)的器官保护作用的临床前研究,以期为早期临床试验的设计提供依据。进行了系统的文献检索。方法学质量根据预先确定的标准进行评估。主要结果是死亡率,其次是评估结果的机制。预先指定的分析评估了可能的主持人对异质性的影响。分析包括对啮齿动物(n = 92)和猪(n = 9)的101项实验研究,它们受到多种伤害,包括:缺血(n = 72),感染(n = 7)和创伤(n = 22)。由于对单项研究中的多种独立干预措施进行了评估,因此总共进行了448次比较。丙戊酸钠(VPA)是最常评估的HDACi(50个研究,203个比较)。所有研究均被认为具有重大的方法学局限性。在没有异质性的器官损伤实验模型中,HDACi降低了死亡率(风险比= 0.52,95%置信区间0.40-0.68,p <0.001)。 HDACi的给药可保护多种物种和损伤,从而保护心肌,大脑和肾脏,这归因于存活细胞信号传导的增加,炎症和程序性细胞死亡的减少。次要结果分析中的异质性是由物种,损伤类型,HDACi类(I类更好),药物(曲古抑菌素更好)和给药时间(损伤前至少6小时)的差异解释的。这些发现突显了HDACi在以急性器官损伤为特征的临床环境中潜在的新颖应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号